lobbying_activities: 2343428

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2343428	2c8df2c3-304b-4428-96ad-34481420fbdf	Q3	MARSHALL & POPP, LLC	401105121	AMGEN USA INC.	2019	third_quarter	PHA	Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office	60000		0	0	2019-10-16T08:46:17.793000-04:00